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A B S T R A C T
The understanding and treatment of multiple myeloma (MM) have dramatically improved in recent years.
However, accurate assessment of the response of myeloma to therapy and its subsequent relapse remains a
difficult task. Criteria have changed over time and new parameters have recently been incorporated to eval-
uate minimal residual disease status. We present a practical approach to assess response and relapse/
progression in myeloma in the context of its treatment. A robust reporting schema is crucial to correctly evaluate
any treatment protocol and compare results across trials. MM is a highly heterogeneous disease with multi-
farious manifestations. To assess the tumor load decline after treatment and its increase during relapse/
progression, numerous parameters need to be taken into account. As our ability and the tools to measure low
levels of disease have improved over time, so have the accepted definitions of response, most recently in August
2016. The goal of this article is to define, describe, and clarify the practical methodological aspects of disease
evaluation in response to therapy and in progression or relapse. We expect this practical manual will help
myeloma professionals and research workers in data collection for registries and databases and clinical trial
reporting.
© 2017 American Society for Blood and Marrow Transplantation.
DEFINITIONS
Plasma Cell Disorders
Plasma cell disorders are characterized by clonal prolif-
eration of plasma cells and clinical consequences secondary
to the malignant plasma cell burden and/or the secretion of
monoclonal intact immunoglobulins or free light chains (FLC)
[1]. In normal individuals, the output of normal plasma cells
results in polyclonal immunoglobulin production. Malig-
nant plasma cells in multiple myeloma (MM) generally secrete
specific clonally derived intact immunoglobulins or their
component light chains. This abnormal immunoglobulin com-
ponent is called the monoclonal immunoglobulin, monoclonal
protein (M protein/M spike/M component), or paraprotein. A
measurable M protein level is generally defined as an M
protein band in serum measuring > 1 g/dL (10 g/L) and an M
protein excretion in urine of > 200 mg/24 hour. The minimum
baseline threshold of 1 g/dL defining measurable M protein
should be distinguished from the usual level of .5 g/dL (5 g/
L) necessary to define progression of disease.
In a subset of patients, the myeloma plasma cells secrete
only monoclonal light chains, which are detected in the urine,
while an intact immunoglobulin paraprotein may not be de-
tectable in the serum. Patients without measurable M protein
in the serum but with at least 200 mg/24 hour excretion of
M protein in the urine are said to have secretory light chain–
only disease. Up to 97% of patients have secretory MM with
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a detectable paraprotein in the serum and/or urine. Those with
no measurable M protein in the urine/serum (who do not
meet the criteria for measurable disease) may have FLC ab-
normalities in the serum, measurable using the “Freelite assay
(The Binding Site Inc., San Diego, CA).” A measurable FLC level
in the blood is generally defined as 10 mg/dL (100 mg/L) of
involved light chain and with an associated abnormal
kappa:lambda ratio (normal range, .26 to 1.65). It is impor-
tant to note that there are currently at least 2 commercially
available tests to measure circulating serum FLCs: the Freelite
assay developed by The Binding Site and the N latex FLC assay
(Siemens Healthcare GmbH, Erlangen, Germany) marketed
by Siemens—these tests are not interchangeable and have dif-
ferent normal ranges. These tests are very useful to monitor
response while tests measuring total light chain in serum and
urines are not useful in clinical practice.
Types of Plasma Cell Disorders
Plasma cell disorders are not limited to MM. The spectrum
of plasma cell disorders includes monoclonal gammopathy of
undetermined significance (MGUS), smoldering MM, plasma
cell leukemia (PCL), solitary plasmacytoma/multiple plasma-
cytomas, AL amyloidosis, and polyneuropathy organomegaly
endocrinopathy monoclonal protein skin changes [2]. More-
over, paraprotein and FLC abnormalities are not exclusive to
plasma cell disorders and may be produced by lymphocytes
in a variety of other malignant and nonmalignant conditions.
MGUS
MGUS is the most common plasma cell disorder and a mi-
nority of individuals with MGUS will develop MM. In 2010,
the International Myeloma Working Group (IMWG) defined
MGUS as the presence of lower levels of serum M protein
(<3 g/dL), a small clonal plasma cell population in the bone
marrow (<10%), and the absence of the myeloma defining
events described below in section 2.2.
MM
Definition of myeloma and making a diagnosis. MM is
defined using a combination of clinical and pathological cri-
teria [3,4]. Criteria include clonal bone marrow plasma cells
≥10% or biopsy-proven plasmacytoma and the presence of 1
or more clinical myeloma-defining events or biomarkers of MM.
Myeloma-defining events. Evidence of end-organ damage,
which can be attributed to the underlying plasma cell pro-
liferative disorder, specifically include the following:
- Hypercalcemia: serum calcium > .25 mmol/L (>1 mg/dL)
higher than the upper limit of normal, or > 2.75 mmol/L
(>11 mg/dL)
- Renal insufficiency: creatinine clearance <40 mL per minute
or serum creatinine >177 μmol/L (>2 mg/dL)
- Anemia: hemoglobin value of >20 g/L (>2 g/dL) below the
lower limit of normal, or a hemoglobin value of <100 g/L
(<10 g/dL)
- Bone lesions: 1 or more osteolytic lesions on the skele-
tal radiography, computed tomography (CT), or positron
emission tomography (PET)-CT scan.
This combination of end-organ damage defines the acronym
CRAB (hyper calcemia, renal impairment, anemia, and bone
lesions).
Myeloma-defining biomarkers of malignancy (in the
absence of CRAB) [5] include the following:
- Clonal bone marrow plasma cell percentage ≥60%
- Serum FLC ratio (involved:uninvolved) ≥ 100
- > 1 focal lytic bone or bone marrow lesion (>5 mm) on a
magnetic resonance imaging (MRI) scan.
These last 3 parameters are not only biomarkers of
myeloma; if present (1 of them is enough), they also indi-
cate that treatment should be initiated. The term symptomatic
myeloma refers to the occurrence of end-organ damage as de-
scribed above and indicates the need for therapy (rather than
the presence of actual symptoms). These new biomarkers add
to the criteria for initiating treatment.
Defining the type of myeloma
Intact immunoglobulin M protein (heavy chain) and/or light
chain type. The hallmark of MM is the production of mono-
clonal immunoglobulins and/or light chains by the clonal
plasma cells. The specific isotype of the heavy or light chain
is characterized by immunofixation electrophoresis (IFE). In
light chain–only myeloma, no heavy chain component is se-
creted, whereas in nonsecretory myeloma, there is no
monoclonal component at all. In most cases of MM, only 1
type of M component is produced throughout the course of
the illness. However, in rare cases, 2 or more (IgG kappa and
IgA kappa, for example) may be present or appear occasion-
ally during the course of the disease in serum/urine (biclonal
gammopathy).
For data collection and entry, the type and magnitude of
the M protein needs to be specified as below. IgG-IgA-IgM-
IgE-IgD indicates the type of heavy chain of the M component,
while kappa-lambda indicates the type of light chain of the
M component.
For biclonal gammopathy with 2 different M protein types,
one should note both M protein types on the data collec-
tion form and indicate which has the highest value. The M
protein with the highest value needs to be considered more
significant and entered into the database. The data entry
should still note the presence of the 2 chain types in the com-
ments field. If a patient has more than 1 M protein spike in
the serum (or urine) at the start of treatment, the sum of the
M proteins should be followed to assess the response. If the
sum of both M proteins is still not at a measurable level, one
may use the FLC test or the bone marrow plasma cell infil-
tration assessment. In the context of deep responses obtained
during autologous stem cell transplantation, 1 or more new
electrophoretic bands (oligoclonal bands) may appear. These
should not be considered pathological or classified as relapse;
it is related to B cell immune reconstitution and these bands
disappear within a few months after transplantation
Measures of the tumor burden in MM
Magnitude of the M protein
Secretory myeloma. The M protein serves as the major bio-
chemical tumor marker for response evaluation and its
magnitude at start of therapy and at each point of retreatment
for progression serves as a baseline to evaluate the re-
sponse. In most cases, the response criteria for MM are
dependent on the magnitude of the M protein and/or its de-
tection. In rare cases, tumor dedifferentiation during recurrent
myeloma may cause plasma cells previously secreting intact
paraproteins, eg, IgG kappa, to produce only a light chain or
even no myeloma related protein at all. In such patients, one
should follow the light chain or nonsecretory myeloma in-
structions described below.
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The magnitude of the monoclonal protein MP in serum
(g/L or mg/dL) is a key parameter to monitor patients with
secretory intact immunoglobulin myeloma, where an intact
monoclonal protein with both heavy and light chain com-
ponents is the measurable M component, but not to monitor
light chain only myeloma or nonsecretory MM. The mono-
clonal protein level is obtained from the serum protein
electrophoresis (SPEP)/IFE report; the total IgG (quantita-
tive IgG) level is not an acceptable alternative.
For IgA, in some cases where a discrete M protein
quantitation cannot be done and IgD myelomas, quantita-
tive immunoglobulin measurements are acceptable for disease
assessment. Compared with IgG, almost all IgD M proteins
are quantitatively small, whereas sometimes the IgA spike
on the SPEP is difficult to measure because of comigration
with other proteins. When using quantitative immunoglobu-
lin measurements, the same percentage change applies as for
the serum M spike to define the response status. For IgD
myeloma (and also in IgM and IgE myeloma), if quantitative
measurement is also not possible, the level of FLC, if el-
evated, is acceptable to monitor the disease but the myeloma
type should be reported as IgD (or IgM/IgE, as appropriate).
In clinical practice, whenever light chains alone are predomi-
nantly detected, an IgD myeloma should be ruled out.
Urinary M proteins or monoclonal immunoglobulin light
chains in urine (g/24 hour). For most patients with secre-
tory light chain MM, this is the most important tumor marker.
Those with intact immunoglobulin MM may also have mea-
surable urinary light chains. Measurable disease for urinary
M protein is defined as >200 mg of monoclonal light chains
excreted during 24-hour urine collection. The current crite-
ria still indicate urinary light chain excretion as the
biochemical marker to follow, although FLC measurement
could supplant this parameter in the future. Indeed, a recent
paper demonstrated an improved sensitivity and prognos-
tic value of serum FLCs over urine measurements [6].
FLC in serum. For the majority of patients without mea-
surable M protein in the serum or 24-hour urine collection
(oligosecretory MM), the serum FLC are the best available
measurable tumor marker [7]. The FLC level determined by
the “Freelite” assay at baseline provides a trackable tumor
marker in these patients with oligosecretory MM. FLC is con-
sidered to be measurable in patients whose involved light
chain (either kappa or lambda) is > 100 mg/L (10 mg/dL) and
who have an abnormal kappa:lambda ratio (abnormal is
outside the range .26 to 1.65 with normal renal function). The
FLC test is also used to quantify light chain myeloma when
the proteinuria is not assessable. It is also 1 of the manda-
tory parameters to define stringent complete response (CR)
and should be obtained if a CR is documented.
Nonsecretory MM and marrow involvement. The bone
marrow plasmacytosis indicates the percentage of plasma cells
among the total nucleated cells in cytologic bone marrow
studies. The marrow plasmacytosis is the only measurable
marker in the minority of patients who are nonsecretory by
electrophoresis of serum/urine and by FLC analysis. The per-
centage of plasma cells may also be estimated by other
techniques such as immunohistochemical (IHC) staining of
marrow trephine biopsies using plasma cell specific markers,
such as CD 138. Flow cytometry of marrow samples typical-
ly underestimates the plasma cell content for technical reasons
and should not be used to calculate/report the plasmacyto-
sis burden.
These parameters are summarized in Table 1 [8-10].
Staging markers
Serum beta-2 microglobulin. The beta-2 microglobulin level
(mg/L) at diagnosis is an important prognostic factor and is
used to stage the disease. It reflects a mixture of tumor load
and renal function.
Serum albumin. Together with beta-2 microglobulin, this
parameter serves to divide MM into 3 groups according to
the International Staging System [11].
Lactate dehydrogenase. If elevated at diagnosis, this is an
adverse prognostic factor and has been incorporated into the
new Revised International Staging System, along with high-
risk genetic markers [12,13]. The genetic markers are obtained
after an immunomagnetic beads CD138 selection is per-
formed and a fluorescent in situ hybridization analysis is
carried out on the nuclei from these purified plasma cells.
Other prognostic staging systems exist, especially based on
molecular risk stratification [14].
Smoldering MM
Asymptomatic patients who meet biochemical or histo-
pathological criteria for MM but do not have myeloma-
defining events are considered to have “smoldering myeloma.”
Treatment is not currently recommended for these pa-
tients, except in clinical trials. Symptoms generally develop
as a result of hypercalcemia, renal insufficiency, anemia, and
bone lesions, as summarized in the acronym CRAB, al-
though further symptoms such as those caused by
hyperviscosity may also require active therapy. As noted pre-
viously, even in “asymptomatic” patients, 3 additional
biomarkers or myeloma-defining events have now been ac-
cepted by the IMWG as indicators for treatment [15] Using
the most recent definition of myeloma requiring treatment,
smoldering myeloma is an indolent form of myeloma with
more than 10% but less than 60% bone marrow plasmacyto-
sis and without myeloma-defining symptoms (CRAB) or
biomarkers (FLC ratio >100 or >1 focal lytic bone lesion on
MRI scan).
PCL
PCL is an aggressive form of plasma cell myeloma char-
acterized by an absolute plasma cell count of at least 2.0 ×
109/L (2000 cells/mm3) in peripheral blood or more than 20%
plasma cells in the peripheral differential white blood cell
count. When discovered de novo at diagnosis, it is called
primary PCL; when discovered at the time of disease relapse,
it is referred to as secondary PCL. Secondary PCL should be
considered as progressive or relapsed myeloma and, there-
fore, should not be reported as primary PCL. The response
criteria for PCL are summarized in Table 2 [16].
Solitary Plasmacytoma/Multiple Plasmacytomas
Plasmacytomas are bone or soft tissue lesions com-
posed of plasma cells with no other findings meeting the
criteria for MM (no significant increase in the percentage of
marrow plasma cells or CRAB criteria/biomarkers of myeloma;
bone destruction may be associated with a single plasma-
cytoma but this does not justify the diagnosis of myeloma).
If numerous plasmacytomas are present, the diagnosis is mul-
tiple plasmacytomas and these cases fulfill the criteria for
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treatment of myeloma. If the pathological criteria for MM are
met in the presence of abnormal plasmacytomas, the disease
is defined as myeloma with plasmacytoma(s).
Waldenstrom macroglobulinemia is not classified as a
plasma cell disorder because it is considered a lymphoma
subtype.
ASSESSING MYELOMA RESPONSE
To assess the response to therapy or progression of disease
in MM, one needs to consider the variations over time of the
biochemical markers, ie, serum or urine M protein or FLC
assays, bone marrow plasmacytosis, and imaging studies for
plasmacytomas and bone lesions. Response evaluation is
usually done (at least) every 3 months in routine clinical prac-
tice, whereas in clinical trials, the frequency is usually every
4 weeks.
M proteins and Free Light Chains: What is measurable
disease?
For patients with intact immunoglobulin secreting MM,
measurable disease is defined as a baseline level of >1 g/dL or
10 g/L of serum M protein (some studies allow >.5 g/dL) or
>200 mg/24 hour of urine M protein. For those with less than
this level of M protein production, a serum-involved FLC level
of ≥10 mg/dL (100 mg/L) is considered to be a measurable
marker and, if this marker is not informative, then it is nec-
essary to assess the bone marrow plasmacytosis. Truly
nonsecretory disease with no measurable M protein or FLC
secretion can only be assessed by marrow plasma cell esti-
mation. Response levels in MM are defined on the basis of
Table 1
Measurement Parameters and Criteria for Change [8-10]
Parameter Measurable Level Degree of Change Required
Serum M protein ≥ 1 g/dL
≥ .5 g/dL in some
studies
CR: SPEP and immunofixation negative
VGPR:
Scenario 1: SPEP negative but positive immunofixation OR
Scenario 2: 90% or greater reduction in serum M protein from the baseline
PR: ≥ 50% reduction in serum M protein from the baseline
SD: Not CR, VGPR, PR. or PD
PD: ≥ 25% increase in serum M protein from the nadir and the absolute increase must be ≥ .5 g/dL
Urine M protein
(24 hour)
≥ 200 mg/24 hour CR: UPEP and immunofixation negative
VGPR: UPEP negative but positive immunofixation OR
Urine M protein < 100 mg/24 hour
PR: ≥ 90% reduction in 24-hour urinary M protein from the baseline or reduction to < 200 mg/24 hour
SD: Not CR, VGPR, PR, or PD
PD: ≥ 25% increase in urine M protein from the nadir and the absolute increase must be ≥ 200 mg/24 hour




≥10 mg/dL for the
involved chain
CR: normal FLC ratio of .26 to 1.65
VGPR: > 90% decrease from the baseline in the difference between the levels of involved and uninvolved FLC
PR: ≥ 50% decrease from the baseline in the difference between the levels of involved and uninvolved FLC
SD: not CR, VGPR, PR, or PD
PD: ≥ 25% increase from the nadir in the difference between the levels of involved and uninvolved FLC.
The absolute increase must be ≥ 10 mg/dL from the nadir (only if serum and urine M protein are not
measurable, otherwise no impact)
Marrow plasma
cells
≥ 30% sCR: absence of marrow clonal cells by IHC/flow cytometry
CR: < 5% plasma cells in the bone marrow
If serum and urine M protein and FLC are not measurable (true nonsecretor):
PR: ≥ 50% reduction in plasma cells from the baseline instead of a reduction in M protein, provided the
baseline bone marrow plasma cell content was ≥ 30%
PD: absolute increase in marrow plasma cells must be ≥ 10%
Plasmacytoma Diameter > 2 cm After radiation, the plasmacytoma is not evaluable to assess the response but must be monitored to assess
PD. Determine the size from the sum of the perpendicular diameters or the longest diameter (if only 1
is reported)
CR: complete regression of the plasmacytoma
VGPR: > 90% decrease in the size of the plasmacytoma
PR: ≥ 50% decrease in the size of the plasmacytoma
PD: > 50% increase in the size of the plasmacytoma and at least 1 cm absolute increase
Bone lesions NA Only for PD, if there are new or increasing bone lesions
PR indicates partial response; SD, stable disease; UPEP, urine protein electrophoresis.
Table 2
Criteria for Response in Plasma Cell Leukemia [16]
Response Criteria
sCR In addition to the sCR criteria for MM, the following
need to be met:
• Absence of malignant plasma cells in the
peripheral blood by flow cytometry
• Absence of extramedullary disease (this
evaluation is necessary)
Cr In addition to the CR criteria for MM, the following need
to be met:
• Absence of plasma cells in the peripheral blood
(by morphology)
• Absence of extramedullary disease
VGPR In addition to the VGPR criteria for MM, the following
need to be met:
• Less than 5% plasma cells in a bone marrow
aspirate
• Absence of plasma cells in the peripheral blood
• Absence of extramedullary disease
PR In addition to the PR criteria for MM, the following need
to be met:
• Between 5% and 25% plasma cells in a bone
marrow aspirate
• Between 1% and 5% plasma cells in the
peripheral blood
• A 50% or greater reduction in the extent of
extramedullary disease
SD Patients who do not meet the criteria for sCR, CR, VGPR,
PR, or PD (defined below) are considered to have SD
PD Any of the PD criteria for MM or more than 5% absolute
increase in plasma cells in the peripheral blood
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changes in these biochemical markers. The magnitudes of
change in these parameters and the corresponding response/
progression levels are summarized in Table 3 [8-10]. Patients
should be categorized as having stable disease until they meet
the criteria for a response category or display progressive
disease (PD).
IMWG response criteria and levels of
response/progression
The first set of criteria defining response to treatment and
progressive/relapsing disease were published in 1998 by the
European Society for Blood and Marrow Transplantation
(EBMT) and Center for International Blood and Marrow Trans-
plant Research [8]. Since then, they have been updated in 2006
with additional clarifications in 2011, 2014, and 2016 by the
IMWG [8-10,15]. The parameters needing to be measured and
the criteria for change are reported in Table 1 and the
minimum data required to assign each response level are given
in Table 3.
By definition, relapse occurs when the patient, who was
in complete remission, experiences a reappearance of
myeloma, while progression refers to patients with an in-
creasing disease burden from a baseline of persistent residual
disease. The minimum level of increase for progression or
relapse is an increase in the monoclonal peak of at least 25%
from the baseline and at least .5 g/dL in magnitude. There are
3 subcategories of relapse: clinical relapse, relapse from com-
plete response, and relapse from minimal residual disease
(MRD) negativity (Table 4) [15,17].
The date of relapse/progression is the date when it was first
detected (although confirmation with an additional assess-
ment is mandatory). Relapse or progression is not necessarily
an indication to start treatment again right away. When treat-
ment is resumed, sometimes weeks, months, or even years
later, this defines the starting date of the subsequent therapy
and a new baseline for response to this line of therapy. By def-
inition, the time to the next treatment is the time interval
between the initiation date of a specific line of therapy and
the date of beginning a subsequent line of therapy (which may
comprise the same drugs as the initial line of therapy).
Recently, criteria for responses deeper than CR and as-
sessment of MRD were defined by consensus [15]. There are
currently 3 approaches to evaluate MRD [18]: cell-based,
molecular-based, or imaging-based. Bone marrow MRD can
be assessed by multicolor flow cytometry, which is a cell-
based technique [19], whereas the molecular techniques
include allele-specific oligonucleotide polymerase chain re-
action and next-generation sequencing (NGS). The current
modern flow cytometric method for MRD includes 8-color
flow cytometry plus kappa and lambda determination for
clonality and is known as next-generation flow; the sensitiv-
ity is 1 in 105 cells and could reach 1 in 106 if enough cells
are counted [20]. NGS, such as the LymphoSIGHT (Scotts-
dale, AZ) platform, is sensitive to the level of 1 remaining
malignant cell in 106. On the basis of these methods, the
IMWG has defined a bone marrow MRD-negative response
category. At present, this committee recommends the use of
NGS or next-generation flow for the detection of MRD in the
bone marrow, depending on the availability of the tech-
niques and the feasibility of individual clinical trials.
Accordingly, when MRD results are reported, the assess-
ment should be qualified by the method(s) used (flow MRD-
negative or sequencing MRD-negative) and the level of
sensitivity (eg, 1 in 105 or 1 in 106 cells). Imaging-based MRD
assessment includes evaluation of the extramedullary disease.
Table 3
Minimum Data Required to Assign Each Level of Response [8-10]
sCR SPEP, UPEP, and IF are negative, normal FLC ratio
Bone marrow: absence of clonal cells by IHC/flow cytometry
Plasmacytomas present at diagnosis or screening are in
complete regression
Bone lesions are non-PD
CR SPEP and UPEP are in CR, IF is negative in serum and urine
FLC in CR (nonsecretors)
Bone marrow in CR
VGPR SPEP and UPEP meet VGPR criteria
FLC in VGPR (nonsecretors)
PR SPEP and UPEP meet PR criteria
FLC in PR (nonsecretors)
SD SPEP and UPEP meet SD criteria
FLC in SD (nonsecretors)
PD PD in any component (SPEP, UPEP, FLC, plasmacytomas, bone
marrow, bone lesions, or serum calcium) as applicable
The baseline values of all measurable disease parameters should be checked
serially to assess response. To confirm CR or sCR, marrow and FLC assess-
ments should also be performed in all cases. A subsequent biochemical study
should be carried out to confirm all biochemical responses, whereas marrow
studies do not need to be reconfirmed. Missing urine electrophoresis results
represent a frequent problem. At this time point, FLC results are not an ad-
equate substitute and the level of response must be reported as nonevaluable
(NE) if there was measurable urine M protein at baseline. Similarly, CR cannot
be confirmed without urine immunofixation. Exceptions to these rules may
be conceded only on the decision of a response monitoring committee and
by consensus. By definition, to assign CR, all parameters in the bone marrow,
serum, and urine should be in CR. Any plasmacytoma present at baseline
should undergo monitoring. All measurable plasmacytomas should have dis-
appeared to be able to confirm CR or have regressed to appropriate levels
for the other categories of response.
IF, immunofixation.
Table 4
IMWG Criteria for Relapse [15,17]
Clinical relapse or progression: can
occur from any level of response
Direct indicators of increasing or progressing disease (see Table 1) and/or end-organ dysfunction (CRAB
parameters);
development of new soft tissue plasmacytomas or myeloma related bone lesions; increase in the size of
existing plasmacytomas or bone lesions, hypercalcemia, a decrease in hemoglobin of ≥2 g/dL, or a rise in
serum creatinine of 2 mg/dL or more
Relapse from CR (only to be used for
clinical trials measuring a disease
free survival end point)
Any 1 or more of the following criteria:
reappearance of serum or urine M protein by immunofixation or electrophoresis;
development of ≥5% plasma cells in the bone marrow;
plus the above criteria
Relapse from the MRD-negative state
(only to be used for clinical trials
measuring a disease-free survival
endpoint)
Any 1 or more of the following criteria:
loss of the MRD-negative state (evidence of clonal plasma cells by NGF or NGS, or a positive imaging study
for recurrence of myeloma);
plus the above criteria
NGF indicates next-generation flow.
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Two techniques are available: PET/CT and MRI [21]. Table 5
summarizes the consensus on MRD criteria.
MYELOMA TREATMENT IN THE CONTEXT OF RESPONSE
ASSESSMENT
Treatment options are determined mainly by the ability
or not to proceed to autologous transplantation, which is
closely related to frailty and fitness (lack of comorbidities)
[22]. For example, among patients older than 70 years, au-
tologous stem cell transplantation (ASCT) is recommended
less often as the procedure may be considered to be too toxic
for the elderly population because of the potential concom-
itant comorbidities. In contrast, for younger patients, ASCT
is generally considered at some point in the course of the
disease, although significant comorbidities may be a contra-
indication even in younger individuals.
ASCT
Transplantation-eligible patients
In the initial (induction) phase, the treatment usually
combines a proteasome inhibitor with an immunomodulatory
drug (IMiD) and steroids. This triplet therapy has many
variants considering that there are currently at least 3 ap-
proved proteasome inhibitors (bortezomib, ixazomib, and
carfilzomib and 3 IMiDs (thalidomide, lenalidomide, and
pomalidomide). The 2 most common combinations are
bortezomib, thalidomide, and dexamethasone (mostly
used in Europe) and bortezomib, lenalidomide, and dexa-
methasone (mostly used in the United States). A treatment
cycle lasts typically 3 weeks and the patients receive 3 to 4
cycles before ASCT. Occasionally, the IMiD component may
be replaced by doxorubicin or cyclophosphamide (cyclo-
phosphamide, bortezomib, and dexamethasone). One study
has shown superiority of bortezomib, thalidomide, and dexa-
methasone over cyclophosphamide, bortezomib, and
dexamethasone with a higher response [23]. An ongoing
study, comparing carfilzomib plus lenalidomide plus dexa-
methasone versus bortezomib plus lenalidomide plus
dexamethasone, will help define which is the better
proteasome inhibitor in the induction phase [24]. After in-
duction, the patients usually achieve remission and
nonprogressive patients proceed to high-dose chemothera-
py followed by ASCT. Approximately 3 months after ASCT,
disease evaluation is performed and further consolidation
or maintenance therapy may be initiated thereafter. Post-
transplantation consolidation generally includes a short period
of treatment of about 2 to 3 months using full doses of
antimyeloma drugs. Maintenance consists of much longer
therapy involving lower doses of drugs, which are given
until the next relapse or for a fixed duration.
Nontransplantation-eligible patients
Historically, the treatment for nontransplantation-eligible
patients was alkylator-based with a doublet combining
melphalan and the steroid prednisone (MP) [25]. Combina-
tions of MP with newer drugs such as thalidomide,
lenalidomide, or bortezomib (Velcade) for a defined period have
been shown to be superior to MP in clinical trials [26] so that
MP and thalidomide or sometimes cyclophosphamide, dexa-
methasone, and thalidomide have become the standard of care
at induction, with bortezomib with MP [27] and more re-
cently MP and lenalidomide assuming this role. The choice of
novel agent is often determined by national funding policies
or insurers’ willingness to pay. More recently, the combina-
tion of lenalidomide plus dexamethasone, given on an extended
basis, was found to be superior to MP and thalidomide and
represents a new standard of care for this patient population
[28]. The triplet combination of bortezomib, lenalidomide, and
dexamethasone has been shown to be associated with supe-
rior overall survival [29]. Additional second-generation agents,
such as carfilzomib, pomalidomide, and ixazomib, are now
being incorporated into first-line clinical trials, while a further
range of effective agents including panobinostat (histone
deacetylase inhibitor) and monoclonal antibodies such as
daratumumab are becoming available.
Allogeneic Stem Cell Transplantation
This procedure is performed less frequently because of its
relatively high mortality and morbidity. The 2 main indica-
tions are (1) young patients in first line with a high risk of
disease progression (eg, poor prognosis cytogenetics) and (2)
patients in first relapse who respond to the relapse treat-
ment (chemosensitive disease) [30]. Various conditioning
regimens have been employed but myeloablative condition-
ing is now rarely used because of the higher transplantation-
related mortality. The current conditioning regimens are
mostly of reduced-intensity or nonmyeloablative regimens.
Therefore, currently in myeloma, allogeneic stem cell trans-
plantation is mostly performed in the relapse setting [31].
The EBMT data registry shows that the numbers are still in-
creasing over the years. Most reports on allografting as a
rescue strategy after a previous autograft have been single-
center or retrospective registry analyses. Some retrospective
studies have compared allogeneic to ASCT. Overall, these
studies showed the feasibility of allografting in relapsed MM
even though they included heterogeneous patient groups and
differences in conditioning regimens and supportive care [32].
Because myeloma patients invariably relapse despite the
improved initial therapies and survival, the case may be made
that relapsed patients after an autograft may most benefit
from the potentially curative effect of graft-versus-myeloma,
especially if high-risk features are present at diagnosis [33].
Table 5
IMWG MRD Criteria (Require a CR) [15]
Flow MRD negative Absence of phenotypically aberrant clonal plasma cells by NGF in bone marrow aspirates using the EuroFlow standard
operation procedure
Sequencing MRD negative Absence of clonal plasma cells by NGS in bone marrow aspirates using the LymphoSIGHT platform
Imaging MRD negative Marrow MRD negativity as defined by NGF or NGS, plus the disappearance of all areas of increased tracer uptake found at
baseline or on a preceding PET/CT scan, or a decrease to a lower mediastinal blood pool SUV, or a decrease to less than
that in the surrounding normal tissue
Sustained MRD negative MRD negativity in the marrow (NGF or NGS, or both) and by imaging as defined above, confirmed in 2 evaluations at least
1 year apart
SUV, standardized uptake value.
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Tandem and Multiple Transplantations
Tandem autologous transplantation
High-dose melphalan followed by ASCT remains 1 of the
best forms of treatment for myeloma as it induces deep re-
mission, which often translates into a long period without
progression/relapse. Two planned ASCTs (tandem ASCT) per-
formed 3 to 6 months apart, usually in the context of first-
line therapy, have been shown to be superior to single ASCT
for some patients and this approach is still commonly
employed, especially in Europe. It is important to note that
there should be no progression of MM between the 2
transplantations.
Recently, 2 studies addressing the role of tandem ASCT
have shown opposite results. The European study demon-
strated superiority of tandem versus single transplantation
[34], especially for high-risk patients, while the United States
study by the Blood and Marrow Transplant Clinical Trials
Network (BMT CTN 0702) did not show any benefit [35].
Tandem autologous allogeneic transplantation
In this type of tandem transplantation, ASCT is often per-
formed before reduced-intensity–conditioned allogeneic
transplantation as part of a planned therapeutic strategy,
which is therefore termed tandem auto-allo transplantation.
The 2 procedures are usually carried out within 3 to 6 months
in the absence of any intervening progression of MM [36,37].
Multiple transplantations (more than 2)
Salvage transplantation (transplantation as second-line
therapy or later) has now been shown to be an effective treat-
ment strategy [38]. With the patients living longer, some of
them may receive more than 2 transplantations. This can
happen if (1) they initially have tandem ASCT and a third ASCT
after relapse, (2) they undergo 1 ASCT and tandem ASCT at
relapse, or (3) they receive single ASCT, a second transplan-
tation at relapse, and a third transplantation after a subsequent
relapse.
PRACTICAL ISSUES IN RESPONSE EVALUATION
Multiple levels of confirmation are necessary for data ac-
curacy. The research coordinator or data manager makes the
initial evaluation. This should be confirmed by the principal
investigator (physician) and, if the patient is participating in
a clinical trial, it will be checked again by the medical monitor
of the trial, where applicable. If the medical monitor dis-
agrees with the physician’s evaluation, a query is sent to the
physician. Nowadays, in international trials, a panel of myeloma
experts review independently all the response/relapse/
progression evaluations. They constitute an independent
review committee.
There are currently 2 commonly used sets of internation-
al criteria: the EBMT/Center for International Blood and
Marrow Transplant Research criteria [8] and the IMWG cri-
teria [9,10] incorporating the FLC test. A specific trial may
arbitrarily use either of them or a modified version. Re-
cently, the MRD assessment has been added to the IMWG
criteria [15].
How to Evaluate Response
To evaluate response, the following considerations are
important:
What is the baseline: at diagnosis or at screening?
If the patient is included in a clinical trial, the M protein
is often determined at 3 time points: at diagnosis, at screening
(when checking to verify that the patient can be included in
the trial), and at baseline, which is day 1 of cycle 1 of treat-
ment according to the protocol. The baseline is the reference
for the measurement of M protein. If the patient is not par-
ticipating in a clinical trial, the baseline is defined by the first
measurement at diagnosis or at the start of therapy. These
2 time points are generally the same unless there is a sig-
nificant interval between diagnosis and starting the treatment,
as may happen in the case of smoldering myeloma progress-
ing to myeloma. In this case, the baseline to use would be
the result at the time of progression to active myeloma
(usually the last value before starting therapy).
To assess response/progression, defining the baseline for
assessment is critical. The baseline for newly diagnosed pa-
tients beginning therapy is clearly the peak values of M protein
(serum or urine), FLC, and marrow plasmacytosis immedi-
ately before the start of therapy. If a baseline value is not
available, an induction response cannot be determined (unless
the patient achieves CR to induction).
In patients proceeding to planned upfront transplanta-
tion after induction without any evidence of disease
progression between induction and transplantation, the base-
line for assessing the response to transplantation remains the
initial time point before induction therapy. The response to
transplantation should be part of the continuum of re-
sponse to initial therapy. For example, a patient who has a
very good partial response (VGPR) going into ASCT and has
a continued VGPR remains in VGPR. If there is any evidence
of disease progression, the baseline for the subsequent line
of therapy after induction is redefined as the peak M protein
at the time of progression (or at the time of starting the new
line of therapy). Once again, if the transplantation follows the
new line of therapy as a planned intervention without any
additional subsequent progression, the baseline for assess-
ing the response to transplantation is the peak M protein at
the time of progression (not at the time point immediately
before the transplantation).
What is a line of treatment?
A line of therapy is defined as 1 or more cycles of a planned
treatment program. When patients have undergone sequen-
tial phases of treatment without intervening progression, such
as induction, collection of peripheral blood stem cells, trans-
plantation, and consolidation/maintenance, this is considered
1 line of treatment. A new line of therapy is initiated as a result
of disease progression or relapse. Such a new line of therapy
for progression or relapse is associated with a new baseline
for disease evaluation.
What are the necessary criteria to define the disease status?
All the criteria must be met to define a response accord-
ing to the guidelines.
There are 3 common time points when the response to a
line of treatment is assessed: at specific time points in the
course of the disease (eg, after 2 or 4 cycles of therapy), im-
mediately before transplantation, or on day 100 after the
transplantation. Alternatively, 1 may choose the time of the
best response, which is the time when the M protein is at
its lowest level or CR (or stringent CR [sCR]) is reached.
For the most common type of MM (secreting an intact
monoclonal immunoglobulin M protein, eg, IgG kappa), the
M protein value measured at baseline (the highest) is com-
pared with the lowest M protein level after the beginning of
therapy. For light chain myeloma, kappa or lambda, values
of the light chain proteinuria (g/24 hour) may be compared
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or if no measurable M protein can be detected, one may use
serum FLC measurements. The percentage of plasma cells in
bone marrow can be determined by aspiration or biopsy (pre-
ferred method). In either case, the origin should be noted.
When the bone marrow plasma cell infiltration is assessed
by both bone marrow aspirate and biopsy, the highest value
of the plasma cell infiltration should be reported.
If a critical data point to establish a level of response is
missing, the evaluation is downgraded to the next lower level,
eg, VGPR instead of CR if a marrow assessment is unavailable/
not done.
The near CR (nCR) status is generally not used anymore,
except by some investigators, although it is still a level of re-
sponse in the EBMT criteria. Therefore, if a patient has no
further serum monoclonal peak and a normal bone marrow
but a positive or unknown serum immunofixation status, the
appropriate level would be nCR according to the EBMT cri-
teria but VGPR according to the IMWG criteria. However, nCR
is not generally in common use and it is usually merged to-
gether with the VGPR status.
For stringent CR, all the following criteria must be met:
all CR criteria plus the absence of clonal marrow plasmacy-
tosis by IHC or flow cytometry and a normal FLC ratio. If even
a single criterion is not met or the data are missing, the re-
sponse cannot be reported as sCR and must be downgraded
to CR.
Each status should be confirmed by second tests giving
consistent results.
Confirmation should be obtained for biochemical markers
but is not necessary for bone marrow or imaging studies.
There is no specific time interval required between the 2
evaluations (previously, 6-week interval was required, but this
is no longer necessary). The response date is not the date of
confirmation but the initial date when the assessment met
the endpoint. In other words, the second test is confirmato-
ry. If the result is not confirmed by a second evaluation, the
status is either nonevaluable (NE) and the prior disease status
remains valid; eg, for a patient who has achieved a con-
firmed PR, a single evaluation meeting the CR end point but
not confirmed would mean that the status is still a PR.
After achievement of a best response and with ongoing
monthly evaluations, it is not recommended to downgrade
the response, eg, from VGPR to PR, unless there is clear ev-
idence for disease progression. Thus, if the monoclonal protein
slightly increases (without meeting the progression crite-
ria) and then decreases at the next evaluation, the response
level should remain VGPR. We do not recommend report-
ing VGPR followed by PR and then back to VGPR in this
situation. The status should remain VGPR for all the 3 time
points above until the criteria for PD are satisfied.
When the M spike is reported as “too small to quanti-
tate” in responding patients, one should assign the M protein
a value of 0 to allow the subsequent calculation of an abso-
lute increase to determine disease progression. Nevertheless,
this situation does not correspond to CR since the parapro-
tein is detectable. The immunoelectropheresis (IEP) should
be reported as positive for the M protein. A negative IEP means
that the SPEP proteins would likely be oligoclonal bands.
How to Evaluate Progression/Relapse
The standard criteria for PD are as follows:
- Relapse occurs whenever the patient moves from CR to
any status with signs of myeloma disease, either biolog-
ical and/or clinical.
- Disease progression can be either biochemical (increase
in an existing monoclonal peak) or clinical. The former pa-
tients may sometimes have no symptoms and may not
need therapy for a long period of time. In other circum-
stances, the M protein increases and symptoms or organ
damage occur concomitantly (clinical relapse).
- Patients are considered to have PD if they meet the cri-
teria for progression for a parameter that was not
considered to be measurable at baseline. For example, a
patient initially having a measurable serum M protein but
no measurable proteinuria, who subsequently reaches
complete remission but during follow-up presents a sig-
nificant monoclonal proteinuria, without any serum
monoclonal peak, should be classified as having PD.
However, for patients with a measurable serum or urine
M spike at baseline, progression cannot be defined on the
basis of increases in serum FLC alone.
- When defining relapse/progression, the result should be
confirmed by a second set of tests. We recommend the
test to be repeated within 6 weeks of original measure-
ment. If it is confirmed, the date of relapse/progression
is the initial date (not that of the confirmatory second test).
Second bone marrow biopsies are not required to confirm
relapse/progression, even in the assessment of non-
secretory patients. Similarly, when a new lytic lesion in
bone or an increase in the size of a plasmacytoma or bone
lesion is detected, it is not necessary to repeat the imaging
procedure.
It is important to realize that in many circumstances, es-
pecially in the case of biochemical relapse or progression,
treatment may not be reinitiated immediately. The patient
may experience a reappearance of the M protein with slow
progression but be treated months or years later.
Conversely, if a new line of antimyeloma therapy was ini-
tiated before confirming PD, one should use the starting date
of the treatment as the date of progression.
How to Deal with Missing and/or Contradictory Data
- If baseline information on the values of the involved
protein is missing, the response cannot be evaluated (NE),
except when CR or sCR was achieved or PD was reported.
- If the IEP result for serum or urine is missing, the test is
considered to be positive and CR cannot be reported (one
should downgrade to VGPR if the other criteria for CR are
met).
- If there is no bone marrow evaluation, complete re-
sponse cannot be reported even if all other parameters
including serum and urine IEP and FLC are normal.
- If no 24-hour urine monoclonal protein measurement is
available, the serum FLC test can be used in clinical situ-
ations, but by strict criteria the urine result is needed for
response assessment.
- When data are missing for 2 or more consecutive cycles,
one should report NE for the specific missing cycle
assessments.
Evaluation of Response in PCL
PCL is the most aggressive variant among plasma cell
dyscrasias and is defined by the presence of >20% plasma cells
in peripheral blood and an absolute peripheral blood plasma
cell count exceeding 2 × 109/L. The clinical features, natural
history, and its poorer prognosis have led to the develop-
ment of modified consensus criteria for response in primary
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PCL [16]. In addition to the MM criteria described above, eval-
uation of the response in PCL includes criteria similar to those
for leukemia. A careful assessment of the extramedullary
disease at diagnosis and response evaluation is required for
all PCL patients, as there is a higher propensity for extra-
medullary disease in PCL. Measurement of the residual disease
in marrow by flow cytometry is necessary when there is no
evidence of plasma cell infiltration using routine morpho-
logic examinations. The additional tests needed to determine
the response in PCL, which are complementary to the bio-
chemical criteria for MM, are summarized in Table 2.
Challenges of Response Assessment in the Era of
Monoclonal Antibodies
Monoclonal antibodies (daratumumab, elotuzumab) are
increasingly used in the treatment of myeloma with great ef-
ficacy. However these therapeutic antibodies may be detected
by serum electrophoresis or immunofixation and confound
the measurement of myeloma-associated M protein in pa-
tients who have recently been treated. The current limit of
detection of most serum IFE assays is approximately 150 μg/
mL M-protein, which is below the serum concentration of
most monoclonal antibodies dosed in the therapeutic range.
Therapeutic monoclonal antibodies so far approved in
myeloma interfere with the detection IgG kappa M-protein
[39]. Several mitigation strategies are being developed to
validly detect low levels of myeloma protein in the pres-
ence of therapeutic monoclonal antibody levels to confirm
VGPR and CR responses. At this time, these strategies are not
widely available but are an issue for patients with IgG kappa
myeloma achieving deep responses with monoclonal anti-
bodies. However, there is an assay for daratumumab that will
account for the antibody in the IEP but not for the Bristol
Myers Squibb compounds (nivolumab and elotuzumab).
Assessing myeloma is an expert discipline and the guide-
lines must be revised on a regular basis as the field is moving
very fast. New forms of therapy have been developed, such
as the monoclonal antibodies, providing a greater depth of
response. As of now, we will therefore need to evaluate the
MRD status using new tools, such as molecular study of the
bone marrow by PCR or flow cytometry, and recent skeletal
imaging techniques, such as PET-CT. These new types of as-
sessment will soon be incorporated into the armament for
disease evaluation and new response/progression criteria will
have to be elaborated.
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